Beyond the barrier: Physiological determinants of nanoformulation availability in the aging brain

Nanomedicine has revolutionized brain-targeted therapeutics; however, most design paradigms remain centered on overcoming the blood-brain barrier while overlooking the dynamic physiological milieu that governs nanoparticle fate after entry. Emerging evidence reveals that barrier penetration alone is insufficient to ensure efficacy, particularly in the aging brain, where vascular stiffness, impaired interstitial flow, reduced glymphatic clearance, and chronic immune activation reshape nanoparticle distribution, retention, and metabolism. Aging introduces structural and functional heterogeneity that can invert design principles validated in young systems, leading to reduced therapeutic performance and unpredictable outcomes. This review integrates current insights into how age-related vascular remodeling, altered cerebrospinal fluid dynamics, and disrupted circadian-metabolic coupling influence nanoformulation performance. We highlight the need for adaptive design strategies, including stimuli-responsive carriers, redox- or enzyme-triggered release systems, and chronopharmacological dosing, that exploit residual rhythmicity and local biochemical cues to optimize delivery. Beyond design, we discuss translational and regulatory implications, emphasizing age-specific protein corona profiling, biomarker-guided patient stratification, and physiologically relevant safety evaluation. Integrating these insights establishes aging not as a confounder but as a biological framework enables the creation of adaptive, context-aware nanomedicines aligned with the evolving physiology of the aging brain which advancing the field toward durable efficacy, enhanced safety, and genuine precision neurotherapeutics.